Clinical trials are now evaluating the potential combination of PARP inhibitors with immunotherapy or other agents in patients with ovarian cancer.
Danielle Ternyila
Advertisement
Articles by Danielle Ternyila
Advertisement
Latest Updated Articles
The Growing Role of PARP Inhibitors in Ovarian CancerPublished: February 11th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
3
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
4
Frequent Continuous Glucose Monitoring Linked to Greater HbA1C Reductions in Adults With T2D
5
